OXIDIEN PHARMACEUTICALS, LLC – Trademark Portfolio
Entity Type: 16
OXIDIEN PHARMACEUTICALS, LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NEPHURE. The owner is based in GAINESVILLE, FL.
747 SW 2nd Avenue, Suite 240
GAINESVILLE, FL 32601
Showing of trademarks Trademarks
Trademark Classifications
OXIDIEN PHARMACEUTICALS, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does OXIDIEN PHARMACEUTICALS, LLC have?
OXIDIEN PHARMACEUTICALS, LLC has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.
What trademark classes does OXIDIEN PHARMACEUTICALS, LLC file in?
OXIDIEN PHARMACEUTICALS, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are OXIDIEN PHARMACEUTICALS, LLC's most well-known trademarks?
OXIDIEN PHARMACEUTICALS, LLC's registered trademark portfolio includes well-known marks such as NEPHURE. These are among 1 currently registered trademark in the portfolio.
What is OXIDIEN PHARMACEUTICALS, LLC's trademark registration success rate?
OXIDIEN PHARMACEUTICALS, LLC has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.